• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Quince Therapeutics Inc.

    8/14/25 4:33:22 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $QNCX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Quince Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    22053A107

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    22053A107


    1Names of Reporting Persons

    Nantahala Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,765,862.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,765,862.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,765,862.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    22053A107


    1Names of Reporting Persons

    Wilmot B. Harkey
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,765,862.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,765,862.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,765,862.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    22053A107


    1Names of Reporting Persons

    Daniel Mack
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,765,862.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,765,862.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,765,862.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Quince Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO, CALIFORNIA, 94080
    Item 2. 
    (a)Name of person filing:

    (1) Nantahala Capital Management, LLC ("Nantahala") (2) Wilmot B. Harkey (3) Daniel Mack (together the "Reporting Persons")
    (b)Address or principal business office or, if none, residence:

    130 Main St. 2nd Floor, New Canaan, Connecticut 06840
    (c)Citizenship:

    (1) Nantahala is a Massachusetts limited liability company. (2) Each of Messrs. Harkey and Mack is a citizen of the United States of America.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    22053A107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of June 30, 2025, Nantahala may be deemed to be the beneficial owner of 4,765,862 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares. The 4,765,862 Shares includes 2,237,562 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of warrants.
    (b)Percent of class:

    As of June 30, 2025, each of the Reporting Persons may be deemed to be the beneficial owner of the following percentage of the total number of Shares outstanding: (1) Nantahala Capital Management, LLC ("Nantahala") : 9.99% (2) Wilmot B. Harkey: 9.99% (3) Daniel Mack: 9.99%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.

     (ii) Shared power to vote or to direct the vote:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 4,765,862 Shares. (2) Wilmot B. Harkey: 4,765,862 Shares. (3) Daniel Mack: 4,765,862 Shares.

     (iii) Sole power to dispose or to direct the disposition of:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.

     (iv) Shared power to dispose or to direct the disposition of:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 4,765,862 Shares. (2) Wilmot B. Harkey: 4,765,862 Shares. (3) Daniel Mack: 4,765,862 Shares.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    BLACKWELL PARTNERS LLC - SERIES A, a fund advised by Nantahala, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of more than five percent of the outstanding shares of common stock beneficially owned by Nantahala reported herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in ss. 240.13d-1(b)(1)(ii)(E). See Item 4(a).
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Nantahala Capital Management, LLC
     
    Signature:/s/ Taki Vasilakis
    Name/Title:Taki Vasilakis / Chief Compliance Officer
    Date:08/14/2025
     
    Wilmot B. Harkey
     
    Signature:/s/ Wilmot B. Harkey
    Name/Title:Wilmot B. Harkey
    Date:08/14/2025
     
    Daniel Mack
     
    Signature:/s/ Daniel Mack
    Name/Title:Daniel Mack
    Date:08/14/2025
    Get the next $QNCX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QNCX

    DatePrice TargetRatingAnalyst
    8/5/2025$9.00Mkt Outperform
    Citizens JMP
    3/24/2025$10.00Outperform
    Oppenheimer
    More analyst ratings

    $QNCX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Quince Therapeutics Inc.

    SCHEDULE 13G - Quince Therapeutics, Inc. (0001662774) (Subject)

    8/14/25 4:33:22 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Quince Therapeutics Inc.

    10-Q - Quince Therapeutics, Inc. (0001662774) (Filer)

    8/11/25 4:06:02 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Quince Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

    8/11/25 4:05:35 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO AND CHIEF MEDICAL OFFICER Thye Dirk bought $107,375 worth of shares (154,500 units at $0.69), increasing direct ownership by 22% to 843,941 units (SEC Form 4)

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    9/3/24 5:38:44 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PRESIDENT Ryan Charles S. bought $31,452 worth of shares (48,387 units at $0.65), increasing direct ownership by 65% to 122,461 units (SEC Form 4)

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    8/22/24 5:51:16 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF BUSINESS OFFICER AND COO Hannah Brendan bought $24,166 worth of shares (38,924 units at $0.62), increasing direct ownership by 15% to 296,540 units (SEC Form 4)

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    8/21/24 6:38:07 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CBO, COO & CCO Hannah Brendan was granted 37,736 shares, increasing direct ownership by 13% to 334,276 units (SEC Form 4)

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    6/23/25 8:48:00 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President Ryan Charles S. was granted 7,548 shares, increasing direct ownership by 6% to 130,009 units (SEC Form 4)

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    6/23/25 8:46:04 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO and CMO Thye Dirk was granted 150,944 shares, increasing direct ownership by 18% to 994,885 units (SEC Form 4)

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    6/23/25 8:43:12 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

    Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026 Closed financing priced at a premium bringing existing cash position to approximately $35 million; expected to provide runway through Phase 3 topline results and into at least second quarter of 2026 Entered into strategic relationship with Option Care Health to support commercial launch of eDSP in the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an

    8/11/25 4:05:00 PM ET
    $OPCH
    $QNCX
    Medical/Nursing Services
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

    Provides access to broad-reaching nationwide network of specialty pharmacy and ambulatory infusion suites across the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it has formed a strategic relationship with Option Care Health, Inc. (NASDAQ:OPCH), the nation's largest independent provider of home and ambulatory infusion services, to support the commercial development and efficient launch of Quince's lead asset, encapsulated dexamethasone sodium phosphate (eDSP) in the U.S., assuming positive study results and subsequent regulatory approval.

    8/7/25 8:00:00 AM ET
    $OPCH
    $QNCX
    Medical/Nursing Services
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

    Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that the company has completed enrollment in its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial to evaluate its lead asset, eDSP, for the treatment of the rare neurodegenerative disease Ataxia-Telangiectasia (A-T). Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, "The completion of enrollment in our pivotal Phase 3 NEAT clinical trial evaluating eDSP for the treatment of A-T is a major milestone for Quin

    7/16/25 8:00:00 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens JMP initiated coverage on Quince Therapeutics with a new price target

    Citizens JMP initiated coverage of Quince Therapeutics with a rating of Mkt Outperform and set a new price target of $9.00

    8/5/25 7:12:02 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Quince Therapeutics with a new price target

    Oppenheimer initiated coverage of Quince Therapeutics with a rating of Outperform and set a new price target of $10.00

    3/24/25 8:40:42 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Leadership Updates

    Live Leadership Updates

    View All

    Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

    Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026 Closed financing priced at a premium bringing existing cash position to approximately $35 million; expected to provide runway through Phase 3 topline results and into at least second quarter of 2026 Entered into strategic relationship with Option Care Health to support commercial launch of eDSP in the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an

    8/11/25 4:05:00 PM ET
    $OPCH
    $QNCX
    Medical/Nursing Services
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

    Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. Hassan Abolhassani, Assistant Professor of Clinical Immunology and Research Specialists in the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet in Stockholm, Sweden, to the company's Scientific Advisory Board (SAB). Dr. Abolhassani becomes the ninth member to join Quince's SAB, which is comprised of leading experts in Ataxia-Telangiectasia (A-T), biochemistry, neurology, immunology, genetic, hematology, pharmacology, and clinical practice. Dr. Mauro Magnani,

    7/10/25 4:05:00 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

    Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. William Whitehouse, Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, and recently retired Consultant Paediatric Neurologist at Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust, to the company's Scientific Advisory Board (SAB). Dr. Whitehouse joins seven founding members of Quince's SAB comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice. Dr. Mauro Magn

    1/23/25 4:05:00 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Financials

    Live finance-specific insights

    View All

    Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

    Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that its Board of Directors (the "Board") unanimously approved the adoption of a limited duration stockholder rights plan (the "Rights Plan") and declared a dividend distribution of one preferred share purchase right on each outstanding share of Quince's common stock. The dividend distribution will be made on April 17, 2023, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on April 5, 2024.

    4/5/23 4:05:00 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

    SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)

    11/14/24 4:00:05 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Quince Therapeutics Inc.

    SC 13D - Quince Therapeutics, Inc. (0001662774) (Subject)

    11/13/24 9:17:26 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

    SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)

    8/6/24 8:04:44 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care